BUSINESSSTAT NEWS
STAT+: Pharmalittle: We’re reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more
AstraZeneca's stock fell amid merger talks with Bristol Myers Squibb, which could create a $400 billion drugmaker, while Amgen disclosed a cybersecurity incident involving stolen patient data. Investors questioned the strategic need for the proposed merger, and Bristol Myers Squibb's shares rose in premarket trading.
Mentioned
Related Signal
Adjacent reporting
- AstraZeneca stock sinks on reports of merger talks with Bristol Myers Squibb
- AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
- AstraZeneca reported tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.
- STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
- AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
- AstraZeneca said to have explored Bristol Myers merger